"When people have heart attacks (or suffer from hypertension) the blood vessels get more rigid," says study author David Ostrov, PhD, an assistant professor in the University of Florida College of Medicine's department of pathology, immunology and laboratory medicine. "We discovered a compound that reverses the fibrosis that makes blood vessels rigid."
The May 1, 2008, edition of the American Heart Association (AHA) journal Hypertension reports that University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and –- in a remarkable finding –- prevents damage to the heart and kidneys in rats with persistent hypertension. The AHA estimates that 72 million people in the United States have high blood pressure, a major risk factor for stroke, heart attack and death.
Angiotensin-converting enzyme, a naturally occurring agent in the human body, plays a key role in the development of high blood pressure. It produces angiotensin II, a potent hormone that triggers the condition and contributes to the development of cardiovascular disease by constricting blood vessels, causing blood pressure to rise. That’s why millions of Americans with hypertension and cardiovascular disease take ACE inhibitors. But these drugs have limited capacity to repair heart function and to reverse tissue damage.
On the other hand, an enzyme know as ACE2 — also naturally occurring — not only lowers levels of angiotensin II, but also converts it to a hormone that helps protect the cardiovascular system. “Only recently has it come to be appreciated that ACE and ACE2 play a very important role in balancing the activity of the other one to maintain normal blood pressure,” says Ostrov. Hypothesizing that activating ACE2 could be beneficial, University of Florida scientists set out to discover a compound that enhances the enzyme’s activity.
Investigators used one of the world’s most powerful supercomputers to process 140,000 prospective drug compounds in a matter of weeks. The computer predicted which molecules would be most likely to enhance the activity of CE2, rotating them in thousand of different orientations to see how they would bind to certain pockets on the enzyme’s surface.
This project had a very small likelihood of succeeding because it’s much easier to inhibit activity rather than to enhance it. By analogy, it’s easier to break something than to build it,” Ostrov said. “If you consider the structure of an enzyme’s active site, it’s easy to see that if you plug up the active site, it’s not going to work. But how can one make the enzyme actually work better? This seemed to be a very significant challenge we were probably not likely to overcome. We tried anyway.”
It worked.
The enzyme exists in two forms: either like a Pac-Man with a mouth that has chomped closed, or like a Pac-Man with a mouth that remains open. The molecule that worked best fit in a structural pocket in the enzyme’s open conformation. Stabilizing the open conformation may be the reason why we enhance the activity of the enzyme.
Early results also show the compound inhibits generalized inflammation, which has significant implications for a number of human ailments, including autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, as well as other diseases involving fibrosis, such as Alzheimer’s.
Watch for more information on this exciting news!
_______________________________________________________________________
Disclaimer: The purpose of this weblog is not to dispense medical advice nor in any way is meant to be construed as diagnostic or prescriptive. Always check with your physician before beginning any new program or trying any of the items discussed in the posts that appear on this site.












Recent Comments